What Investors Got Wrong About Arcus Biosciences Before The Drop

Arcus Biosciences has spent most of 2026 in headlines for its widening losses, Q2 revenue of US$41 million, and a series of mixed trial and partnership updates around casdatifan and the rest of its pipeline. Holding Arcus Biosciences from the start of the year would have meant a 23.4% loss, including dividends. If you had made that call on 1 January, how should the setback in domvanalimab and the push behind casdatifan now reshape expectations for this business?

The useful thing about a Narrative is that the reasoning is checkable: the assumptions sit beside the argument, and together they imply an estimated Fair Value you can disagree with.

Arcus Biosciences has already moved. Pinpoint other ways to investigate the theme among 33 healthcare AI stocks.

The Two Arcus Biosciences Stories Investors Had To Weigh

The shares cost US$23.83 at the start of the period, and anyone looking at Arcus Biosciences then had to choose between two very different but plausible stories.

On the optimistic side, the bullish Narrative put Fair Value at US$28.45. That view leaned on casdatifan's late stage development in renal cell carcinoma and assumed annual revenue growth of 7.7% with profit margins moving from a loss to 16.1%.

The bearish Narrative argued for Fair Value of US$12. It focused on dependency on partners such as Gilead and assumed revenue would decline 5.2% a year, even if profit margins eventually reached 14.1% on a high future P/E of 111.9x.

What The 2026 Evidence Did To The Arcus Biosciences Story

The key development was Arcus Biosciences leaning into casdatifan, with Phase 3 kidney cancer trials advancing and multiple new combination studies signed, which supported the optimistic case that RCC could anchor the business. At the same time, total revenue fell to US$41 million in Q2 2026 from US$160 million a year earlier and the firm reported a US$91 million loss, so profitability in the bullish scenario remained unproven. Overall, the evidence cut both ways.

The lesson is that a thesis built on one lead drug hinges on two checks. First, track whether trials progress toward registrational studies on the promised timelines. Second, compare that to the direction of reported revenue and net margin to see if the story is turning into a financial engine or just a larger cash drain.

What Arcus Biosciences' Share Price Drop Now Asks You To Believe

Arcus Biosciences trades at US$17.85 from the start of the year, down 23.4%. The selected Narrative puts Fair Value above that price and ties the argument tightly to casdatifan, RCC and a second leg in immunology.

For that higher figure to be reached, casdatifan likely needs to support broad, durable use across renal cell carcinoma lines while newer immunology assets mature.

"Arcus Biosciences is positioning casdatifan as a backbone therapy in clear cell renal cell carcinoma across first, second and late lines. The company is using the ARC-20 platform to generate monotherapy and combination data that support registrational studies like PEAK-1 and PEAK-20, which could broaden future revenue sources beyond what single-line use would support."

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there

Looking Beyond Arcus Biosciences

Arcus Biosciences leans on a few key trials. You could also look at a business tackling chronic disease from another angle.

Where Arcus chases oncology and immunology through one pipeline, this other drug maker pushes into obesity and diabetes treatment.

It is building a mix of injectables and oral therapies, plus cardiovascular and metabolic drugs, all aimed at long running conditions.

Alongside that, it is working on cancer, autoimmune disease, migraine and brain health, so potential revenue does not rest on one category.

If that broader portfolio keeps attracting demand, your research universe around Arcus might look very different.

That argument has a Narrative and a number behind it. → See the company one Narrative values 17% above its price

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com